LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 158

Search options

  1. Article ; Online: Neuroinflammation: Fanning the fire of l-dopa-induced dyskinesia.

    Bishop, Christopher

    Movement disorders : official journal of the Movement Disorder Society

    2020  Volume 34, Issue 12, Page(s) 1758–1760

    MeSH term(s) Animals ; Antiparkinson Agents/adverse effects ; Cytokines/metabolism ; Disease Models, Animal ; Dyskinesia, Drug-Induced/physiopathology ; Humans ; Inflammation/chemically induced ; Inflammation/pathology ; Levodopa/adverse effects ; Nervous System Diseases/chemically induced ; Nervous System Diseases/pathology ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Tumor Necrosis Factor-alpha/metabolism
    Chemical Substances Antiparkinson Agents ; Cytokines ; Tumor Necrosis Factor-alpha ; Levodopa (46627O600J)
    Language English
    Publishing date 2020-01-09
    Publishing country United States
    Document type Editorial
    ZDB-ID 607633-6
    ISSN 1531-8257 ; 0885-3185
    ISSN (online) 1531-8257
    ISSN 0885-3185
    DOI 10.1002/mds.27900
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Book ; Online: COVID-19 Assignment Details

    Bishop, Christopher

    COVID-19 Student Journal Project

    2020  

    Keywords COVID-19 ; student works ; journals ; HY201 ; HY202 ; Epidemiology ; United States History ; covid19
    Publishing date 2020-05-01T07:00:00Z
    Publisher JSU Digital Commons
    Publishing country us
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article: Dopamine D3 Receptor Plasticity in Parkinson's Disease and L-DOPA-Induced Dyskinesia.

    Lanza, Kathryn / Bishop, Christopher

    Biomedicines

    2021  Volume 9, Issue 3

    Abstract: Parkinson's Disease (PD) is characterized by primary and secondary plasticity that occurs in response to progressive degeneration and long-term L-DOPA treatment. Some of this plasticity contributes to the detrimental side effects associated with chronic ... ...

    Abstract Parkinson's Disease (PD) is characterized by primary and secondary plasticity that occurs in response to progressive degeneration and long-term L-DOPA treatment. Some of this plasticity contributes to the detrimental side effects associated with chronic L-DOPA treatment, namely L-DOPA-induced dyskinesia (LID). The dopamine D3 receptor (D3R) has emerged as a promising target in LID management as it is upregulated in LID. This upregulation occurs primarily in the D1-receptor-bearing (D1R) cells of the striatum, which have been repeatedly implicated in LID manifestation. D3R undergoes dynamic changes both in PD and in LID, making it difficult to delineate D3R's specific contributions, but recent genetic and pharmacologic tools have helped to clarify its role in LID. The following review will discuss these changes, recent advances to better clarify D3R in both PD and LID and potential steps for translating these findings.
    Language English
    Publishing date 2021-03-19
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2720867-9
    ISSN 2227-9059
    ISSN 2227-9059
    DOI 10.3390/biomedicines9030314
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Book ; Online: Conformal mapping in linear time

    Bishop, Christopher J.

    2020  

    Abstract: Given any $\epsilon >0$ and any planar region $\Omega$ bounded by a simple n-gon $P$ we construct a ($1 + \epsilon)$-quasiconformal map between $\Omega$ and the unit disk in time $C(\epsilon)n$. One can take $ C(\epsilon) = C + C \log (1/\epsilon) \log \ ... ...

    Abstract Given any $\epsilon >0$ and any planar region $\Omega$ bounded by a simple n-gon $P$ we construct a ($1 + \epsilon)$-quasiconformal map between $\Omega$ and the unit disk in time $C(\epsilon)n$. One can take $ C(\epsilon) = C + C \log (1/\epsilon) \log \log (1/\epsilon)$.

    Comment: 126 pages, 57 figures
    Keywords Mathematics - Complex Variables ; Computer Science - Computational Geometry ; Primary 30C35 ; Secondary: 30C85 ; 30C62
    Publishing date 2020-07-13
    Publishing country us
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Book ; Online: Optimal angle bounds for quadrilateral meshes

    Bishop, Christopher J.

    2020  

    Abstract: We show that any simple planar n-gon can be meshed in linear time by $O(n)$ quadrilaterals with all new angles bounded between $60$ and $120$ degrees. ... Comment: 27 pages, 22 ... ...

    Abstract We show that any simple planar n-gon can be meshed in linear time by $O(n)$ quadrilaterals with all new angles bounded between $60$ and $120$ degrees.

    Comment: 27 pages, 22 figures
    Keywords Computer Science - Computational Geometry ; Mathematics - Complex Variables ; 30C20 (primary) 30C30 ; 65D17 (secondary)
    Publishing date 2020-07-15
    Publishing country us
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  6. Article ; Online: Striatal serotonin transporter gain-of-function in L-DOPA-treated, hemi-parkinsonian rats.

    Conti Mazza, Melissa M / Centner, Ashley / Werner, David F / Bishop, Christopher

    Brain research

    2023  Volume 1811, Page(s) 148381

    Abstract: L-DOPA is the standard treatment for Parkinson's disease (PD), but chronic treatment typically leads to L-DOPA-induced dyskinesia (LID). LID involves a complex interaction between the remaining dopamine (DA) system and the semi-homologous serotonin (5-HT) ...

    Abstract L-DOPA is the standard treatment for Parkinson's disease (PD), but chronic treatment typically leads to L-DOPA-induced dyskinesia (LID). LID involves a complex interaction between the remaining dopamine (DA) system and the semi-homologous serotonin (5-HT) system. Since serotonin transporters (SERT) have some affinity for DA uptake, they may serve as a functional compensatory mechanism when DA transporters (DAT) are scant. DAT and SERT's functional contributions in the dyskinetic brain have not been well delineated. The current investigation sought to determine how DA depletion and L-DOPA treatment affect DAT and SERT transcriptional processes, translational processes, and functional DA uptake in the 6-hydroxydopamine-lesioned hemi-parkinsonian rat. Rats were counterbalanced for motor impairment into equally lesioned treatment groups then given daily L-DOPA (0 or 6 mg/kg) for 2 weeks. At the end of treatment, the substantia nigra was processed for tyrosine hydroxylase (TH) and DAT gene expression and dorsal raphe was processed for SERT gene expression. The striatum was processed for synaptosomal DAT and SERT protein expression and ex vivo DA uptake. Nigrostriatal DA loss severely reduced DAT mRNA and protein expression in the striatum with minimal changes in SERT. L-DOPA treatment, while not significantly affecting DAT or SERT alone, did increase striatal SERT:DAT protein ratios. Using ex vivo microdialysis, L-DOPA treatment increased DA uptake via SERT when DAT was depleted. Overall, these results suggest that DA loss and L-DOPA treatment uniquely alter DAT and SERT, revealing implications for monoamine transporters as potential biomarkers and therapeutic targets in the hemi-parkinsonian model and dyskinetic PD patients.
    MeSH term(s) Rats ; Animals ; Levodopa/therapeutic use ; Serotonin Plasma Membrane Transport Proteins/metabolism ; Serotonin/metabolism ; Gain of Function Mutation ; Rats, Sprague-Dawley ; Dopamine/metabolism ; Corpus Striatum/metabolism ; Parkinson Disease/drug therapy ; Parkinson Disease/metabolism ; Oxidopamine/metabolism
    Chemical Substances Levodopa (46627O600J) ; Serotonin Plasma Membrane Transport Proteins ; Serotonin (333DO1RDJY) ; Dopamine (VTD58H1Z2X) ; Oxidopamine (8HW4YBZ748)
    Language English
    Publishing date 2023-04-29
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 1200-2
    ISSN 1872-6240 ; 0006-8993
    ISSN (online) 1872-6240
    ISSN 0006-8993
    DOI 10.1016/j.brainres.2023.148381
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Effect of Foot Orthoses on Running Economy and Foot Longitudinal Arch Motion in Runners With Flat-Arched Feet.

    Crago, Daniel / Arnold, John B / Bishop, Christopher

    International journal of sports physiology and performance

    2021  Volume 16, Issue 10, Page(s) 1401–1407

    Abstract: Purpose: To determine the effect of manipulating foot longitudinal arch motion with different-stiffness foot orthoses on running economy (RE) in runners with flat-arched feet and if changes in arch deformation and recoil were associated with changes in ... ...

    Abstract Purpose: To determine the effect of manipulating foot longitudinal arch motion with different-stiffness foot orthoses on running economy (RE) in runners with flat-arched feet and if changes in arch deformation and recoil were associated with changes in RE.
    Methods: Twenty-three recreational distance runners performed 5-minute submaximal treadmill runs at 12 km·h-1, in the following 3 conditions in a randomized order: (1) footwear only, (2) flexible orthoses (reduced arch thickness), and (3) standard orthoses. The RE (submaximal steady-state oxygen consumption [VO2submax]) and sagittal arch range of motion were compared among conditions using a repeated-measures analysis of variance and effect sizes (Cohen d). Pearson correlation coefficients were used to determine the association between the change in the sagittal arch range of motion and VO2submax.
    Results: Compared with standard orthoses, the mean VO2submax was significantly lower in both the flexible orthoses (-0.8 mL·kg-1·min-1, P < .001, d = 0.35) and footwear-only conditions (-1.2 mL·kg-1·min-1, P < .001, d = 0.49). The change in VO2submax between the flexible orthoses and footwear-only conditions was significantly positively correlated with the change in sagittal arch range of motion (r = .591, P = .005).
    Conclusion: Conventional foot orthoses were associated with poorer RE compared with flexible orthoses and footwear alone. Changes in arch deformation were positively correlated to changes in oxygen consumption, indicating that foot orthoses that limit arch deformation and recoil degrade RE. Foot orthoses that facilitate energy storage and release in the foot longitudinal arch may be advisable for athletes prescribed these devices for clinical purposes to maintain optimal running performance.
    MeSH term(s) Biomechanical Phenomena ; Foot ; Foot Orthoses ; Humans ; Range of Motion, Articular ; Running
    Language English
    Publishing date 2021-03-10
    Publishing country United States
    Document type Journal Article
    ISSN 1555-0273
    ISSN (online) 1555-0273
    DOI 10.1123/ijspp.2020-0717
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: The effects of L-DOPA on gait abnormalities in a unilateral 6-OHDA rat model of Parkinson's disease.

    Holden, Hannah / Venkatesh, Shruti / Budrow, Carla / Nezaria, Sareen / Coyle, Michael / Centner, Ashley / Lipari, Natalie / McManus, Grace / Bishop, Christopher

    Physiology & behavior

    2024  Volume 281, Page(s) 114563

    Abstract: Parkinson's Disease (PD) is a neurodegenerative movement disorder characterized by dopamine (DA) cell loss in the substantia nigra pars compacta (SNc). As PD progresses, patients display disruptions in gait such as changes in posture, bradykinesia, and ... ...

    Abstract Parkinson's Disease (PD) is a neurodegenerative movement disorder characterized by dopamine (DA) cell loss in the substantia nigra pars compacta (SNc). As PD progresses, patients display disruptions in gait such as changes in posture, bradykinesia, and shortened stride. DA replacement via L-DOPA alleviates many PD symptoms, though its effects on gait are not well demonstrated. This study aimed to assess the relationship between DA lesion, gait, and deficit-induced reversal with L-DOPA. To do so, Sprague-Dawley rats (N = 25, 14 males, 11 females) received unilateral medial forebrain bundle (MFB) DA lesions with 6-hydroxydopamine (6-OHDA). An automated gait analysis system assessed spatiotemporal gait parameters pre- and post-lesion, and after various doses of L-DOPA (0, 3, or 6 mg/kg; s.c.). The forepaw adjusting steps (FAS) test was implemented to evaluate lesion efficacy while the abnormal involuntary movements (AIMs) scale monitored the emergence of L-DOPA-induced dyskinesia (LID). High performance liquid chromatography (HPLC) assessed changes in brain monoamines on account of lesion and treatment. Results revealed lesion-induced impairments in gait, inclusive of max-contact area and step-sequence alterations that were not reversible with L-DOPA. However, the emergence of AIMs were observed at higher doses. Post-mortem, 6-OHDA lesions induced a loss of striatal DA and norepinephrine (NE), while prefrontal cortex (PFC) displayed noticeable reduction in NE but not DA. Our findings indicate that hemiparkinsonian rats display measurable gait disturbances similar to PD patients that are not rescued by DA replacement. Furthermore, non-DA mechanisms such as attention-related NE in PFC may contribute to altered gait and may constitute a novel target for its treatment.
    Language English
    Publishing date 2024-05-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 3907-x
    ISSN 1873-507X ; 0031-9384
    ISSN (online) 1873-507X
    ISSN 0031-9384
    DOI 10.1016/j.physbeh.2024.114563
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Heptadecanoic Acid Is Not a Key Mediator in the Prevention of Diet-Induced Hepatic Steatosis and Insulin Resistance in Mice.

    Bishop, Christopher A / Machate, Tina / Henkel, Janin / Schulze, Matthias B / Klaus, Susanne / Piepelow, Karolin

    Nutrients

    2023  Volume 15, Issue 9

    Abstract: Epidemiological studies found that the intake of dairy products is associated with an increased amount of circulating odd-chain fatty acids (OCFA, C15:0 and C17:0) in humans and further indicate that especially C17:0 is associated with a lower incidence ... ...

    Abstract Epidemiological studies found that the intake of dairy products is associated with an increased amount of circulating odd-chain fatty acids (OCFA, C15:0 and C17:0) in humans and further indicate that especially C17:0 is associated with a lower incidence of type 2 diabetes. However, causal relationships are not elucidated. To provide a mechanistic link, mice were fed high-fat (HF) diets supplemented with either milk fat or C17:0 for 20 weeks. Cultured primary mouse hepatocytes were used to distinguish differential effects mediated by C15:0 or C17:0. Despite an induction of OCFA after both dietary interventions, neither long-term milk fat intake nor C17:0 supplementation improved diet-induced hepatic lipid accumulation and insulin resistance in mice. HF feeding with milk fat actually deteriorates liver inflammation. Treatment of primary hepatocytes with C15:0 and C17:0 suppressed JAK2/STAT3 signaling, but only C15:0 enhanced insulin-stimulated phosphorylation of AKT. Overall, the data indicate that the intake of milk fat and C17:0 do not mediate health benefits, whereas C15:0 might be promising in further studies.
    MeSH term(s) Humans ; Animals ; Mice ; Insulin Resistance ; Diabetes Mellitus, Type 2/prevention & control ; Fatty Acids ; Fatty Liver ; Diet, High-Fat/adverse effects
    Chemical Substances margaric acid (V987Y9OZ8L) ; Fatty Acids
    Language English
    Publishing date 2023-04-24
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2518386-2
    ISSN 2072-6643 ; 2072-6643
    ISSN (online) 2072-6643
    ISSN 2072-6643
    DOI 10.3390/nu15092052
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.

    Lanza, Kathryn / Bishop, Christopher

    Journal of neural transmission (Vienna, Austria : 1996)

    2018  Volume 125, Issue 8, Page(s) 1203–1216

    Abstract: Dopamine (DA) replacement therapy with L-3,4-dihydroxyphenylalanine (L-DOPA) continues to be the gold-standard treatment for Parkinson's disease (PD). Despite clear symptomatic benefit, long-term L-DOPA use often results in the development of L-DOPA- ... ...

    Abstract Dopamine (DA) replacement therapy with L-3,4-dihydroxyphenylalanine (L-DOPA) continues to be the gold-standard treatment for Parkinson's disease (PD). Despite clear symptomatic benefit, long-term L-DOPA use often results in the development of L-DOPA-induced dyskinesia (LID), significantly reducing quality of life and increasing costs for PD patients and their caregivers. Accumulated research has demonstrated that several pre- and post-synaptic mechanisms contribute to LID development and expression. In particular, raphe-striatal hyperinnervation and unregulated DA release from 5-HT terminals is postulated to play a central role in LID manifestation. As such, manipulation of the 5-HT system has garnered considerable attention. Both pre-clinical and clinical research has supported the potential of modulating the 5-HT system for LID prevention and treatment. This review discusses the rationale for continued investigation of several potential anti-dyskinetic strategies including 5-HT stimulation of 5-HT1A and 5-HT1B receptors and blockade of 5-HT2A receptors and SERT. We present the latest findings from experimental and clinical investigations evaluating these 5-HT targets with the goal of identifying those with translational promise and the challenges associated with each.
    MeSH term(s) Animals ; Antiparkinson Agents/adverse effects ; Dyskinesia, Drug-Induced ; Humans ; Levodopa/adverse effects ; Receptors, Serotonin/drug effects ; Receptors, Serotonin/metabolism ; Serotonin/metabolism ; Serotonin/pharmacology ; Serotonin Receptor Agonists/pharmacology
    Chemical Substances Antiparkinson Agents ; Receptors, Serotonin ; Serotonin Receptor Agonists ; Serotonin (333DO1RDJY) ; Levodopa (46627O600J)
    Language English
    Publishing date 2018-01-05
    Publishing country Austria
    Document type Journal Article ; Review
    ZDB-ID 184163-4
    ISSN 1435-1463 ; 0300-9564
    ISSN (online) 1435-1463
    ISSN 0300-9564
    DOI 10.1007/s00702-017-1837-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top